A novel mi3 VLP nanoparticle vaccine displaying ESAT-6 -PPE57 -PPE68 -EsxV antigens exhibits superior immunogenicity and Mycobacterium tuberculosis growth inhibition
International Immunopharmacology · 2026-03 · 173 · 116264
DOI: 10.1016/j.intimp.2026.116264 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-03. Verfasst von Qi Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Ningxia University, Yinchuan 750021, China; Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnost…. Hauptthemen laut MEDLINE: Antigens, Bacterial, Mycobacterium tuberculosis, Tuberculosis Vaccines, Bacterial Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China, Foundation for Innovative Research Groups of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Tuberculosis (TB) is an ancient disease caused by Mycobacterium tuberculosis (Mtb), and vaccination represents the most effective strategy for preventing and controlling TB infection. In this study, we screened 200 antigens distributed across different infection stages/types in the Mtb genome. Using IEDB and VaxiJen v2.0 algorithm, we identified 10 Mtb-specific T cell target antigens. Further selection based on IFN-γ expression levels in PBMC from QFT+ and QFT- individuals after stimulation with the 10 antigens, led to the identification of ESAT-6, PPE57, PPE68, and EsxV as four candidate antigens. These antigens were displayed on the surface of mi3 virus-like particles (VLP) via the Spycatcher/SpyTag system and formulated with adjuvant AS01E to construct a multivalent VLP nanoparticle vaccine (EPPE+mi3/AS01E). The immunogenicity of this vaccine was evaluated in C57BL/6 mice following a three-dose immunization schedule, and its protective efficacy was assessed using the mycobacterial growth inhibition assay (MGIA). Our results demonstrated that EPPE+mi3/AS01E elicited robust Th1, Th2, and Th17 cellular immune responses, as well as potent antigen-specific humoral immune responses. It significantly enhanced the capacity of splenic lymphocytes to inhibit the in vitro growth of Mtb H37Rv, outperforming both the subunit vaccine (EPPE/AS01E) and BCG alone. When administered as a BCG booster, EPPE+mi3/AS01E synergistically enhanced the immunological response and protective efficacy conferred by BCG. Collectively, the mi3 VLP multi-antigen nanovaccine developed in this study demonstrated strong immunogenicity and significant inhibition of Mtb growth, highlighting it as a promising vaccine candidate for further development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Ningxia University, Yinchuan 750021, China; Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, Guangdong Medical Univers…
- Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, China.
- Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China; Dongguan Key Laboratory of Molecular Immunology…
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Nationa Clinical Research Center for Infectious Diseases, China-Singapore Belt and Road Joint Laboratory on lnfection Research and Drug Developmen…
- State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of Tuberculosis Research, Department of Clinical Laboratory, Guangzhou Chest Hospital, Institute of Tuberculosis, Guangzhou Medical University, Guang…
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
Zitieren
APA
Chen, Q., Huang, N., Liao, M., Zhang, X., Aiman, S., Li, S., Chen, M., Wang, J., Ouyang, P., Zhang, Y., Zhu, J., Huang, K., & Xu, G. (2026). A novel mi3 VLP nanoparticle vaccine displaying ESAT-6 -PPE57 -PPE68 -EsxV antigens exhibits superior immunogenicity and Mycobacterium tuberculosis growth inhibition. International Immunopharmacology, 173, 116264. https://doi.org/10.1016/j.intimp.2026.116264
Vancouver
Chen Q, Huang N, Liao M, Zhang X, Aiman S, Li S, et al. A novel mi3 VLP nanoparticle vaccine displaying ESAT-6 -PPE57 -PPE68 -EsxV antigens exhibits superior immunogenicity and Mycobacterium tuberculosis growth inhibition. International Immunopharmacology. 2026;173:116264. doi:10.1016/j.intimp.2026.116264
BibTeX
@article{Chen2026,
author = {Chen, Qi and Huang, Na and Liao, Mingfeng and Zhang, Xiqian and Aiman, Sara and Li, Sihui and Chen, Mei and Wang, Junhuan and Ouyang, Ping and Zhang, Ying and Zhu, Jialou and Huang, Kaisong and Xu, Guangxian},
title = {A novel mi3 VLP nanoparticle vaccine displaying ESAT-6 -PPE57 -PPE68 -EsxV antigens exhibits superior immunogenicity and Mycobacterium tuberculosis growth inhibition},
journal = {International Immunopharmacology},
year = {2026},
volume = {173},
pages = {116264},
doi = {10.1016/j.intimp.2026.116264}
}
EUVIMED